Novum Vitrium Cervical Cage in Anterior Cervical Discectomy and Fusion

  • STATUS
    Recruiting
  • End date
    Feb 9, 2024
  • participants needed
    168
  • sponsor
    Bio2 Technologies
Updated on 9 April 2021

Summary

A prospective, multicenter, randomized, concurrently controlled, noninferiority clinical trial to compare the safety and effectiveness of instrumented Bio2 Vitrium Cervical Interbody Device in anterior cervical discectomy and fusion (ACDF) with structural allograft bone and local autologous bone graft in treating patients with a symptomatic degenerative cervical disc disease at one level from C3/C4 to C7/T1.

Description

The study will evaluate if Bio2 Vitrium Cervical Interbody Device (VCIBD) is non-inferior to allograft cage in single-level ACDF with the use of local autologous bone. VCIBD is a restorable cervical interbody cage for the treatment of fusion, following discectomy, of the cervical spine from C3/C4 disc space to the C7/T1 disc space. The material used to manufacture the implant is 13-93 bioactive glass, which is a silicate-based material as described in ASTM F1538-03(R2017). The implant has high porosity and strength and does not contain any biological material or constitute a combination product. The device has a central lumen for packing with autograft. VCIBD is intended to be used with a supplemental fixation system.

The device, when placed between the vertebrae, provides mechanical stability and prevents subsidence prior to bone ingrowth. It restores and maintains the intervertebral space during the fusion process. The porosity and material characteristics provide an osteoconductive matrix that supports bone ingrowth. Additional stabilization is provided by supplemental fixation using anterior cervical plate. The implant incorporates a central lumen, which allows for the cage to be packed with autogenous bone graft.

Details
Condition Symptomatic Cervical Disc Disease
Treatment Bio2 Vitrium® Cervical Interbody Device, Allograft Cage, Allograft Ring or Block, Novum Vitrium® Cervical Interbody Device
Clinical Study IdentifierNCT03828136
SponsorBio2 Technologies
Last Modified on9 April 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Symptomatic cervical disc disease (SCDD) in the one vertebral level between C3/C4 to C7/T1, defined as neck or arm (radicular) pain, or functional or neurological deficit and correlated with radiculopathy or myelopathy or radiographic confirmation (by CT, MRI, x-ray, etc.) of any of the following
Herniated nucleus pulposus
Spondylosis (defined by the presence of osteophytes); or
Loss of disc height
Requires only one cervical vertebral level to be surgically treated, confirmed radiologically by Xray, CT, or MRI and correlated with neurologic examination prior to enrollment
Age between 22 and 70 years (inclusive)
Skeletally mature patients
Failed at least 6 weeks of conservative treatment (e.g. medication, physical therapy), or exhibit progressive symptoms or signs of spinal cord/nerve root compression with continued non-operative care
Neck Disability Index (NDI) Questionnaire score of at least 30 (on a scale from 0 to 100)
Able to read and Understand all documents used in this study, including the Informed Consent and patient-reported outcome questionnaires
Understand and read English at elementary level
Patient must understand and sign the Informed Consent document that has been approved by the Ethics committee, Institutional review Board and the FDA

Exclusion Criteria

More than one vertebral level requiring treatment, confirmed radiologically by X-ray, CT, or MRI
Cervical instability
Prior fusion surgery at any cervical vertebral level
Prior surgery at the level to be treated with the exception of surgery that does not require the use of hardware and/or the treatment of facet disease
Severe facet disease
Clinically compromised vertebral bodies at the affected level(s) due to current or past trauma
Neck or arm pain of unknown etiology
Osteoporosis, osteopenia, Paget's disease, osteomalacia or any other metabolic bone disease
Osteoporosis is defined as history of fragility fracture and Dexa (DXA) T-score < -2.5 or QCT T-score < 80mg/cubic cm. History of a fragility fracture requires that a DXA scan or QCT scan is completed
Pregnant or interested in becoming pregnant in the next 2 years
Active systemic or local infection
History of severe allergy or anaphylaxis especially to titanium, polyethylene, cobalt, chromium or molybdenum
Taking medications or any drug known to potentially interfere with bone/soft tissue healing (e.g., steroids, bisphosphonates)
Rheumatoid arthritis or another autoimmune disease that affects musculoskeletal system
Acquired immune deficiency syndrome (AIDS) or an AIDS-related complex
Active malignancy or history of invasive malignancy within the last five years, except for superficial basal cell carcinoma or squamous cell carcinoma of the skin that has been definitely treated; patients with carcinoma in situ of the uterine cervix treated definitely more than 1 year prior to enrollment may enter the study
Neuromuscular disorders such as muscular dystrophy, spinal muscular atrophy, and amyotrophic lateral sclerosis
Pre-existent neurologic or mental disorder which would preclude accurate evaluation and followup (i.e. Alzheimer's disease, Parkinson's disease, unstable psychiatric disorder with hallucinations and/or delusions or schizophrenia)
Substance use disorder categorized as moderate to severe as defined in DSM-V
Mental/Psychiatric disorder as defined in DSM-V
Alcohol abuse disorder categorized as moderate to severe as defined in DSM-V
Current Smokers
Use of bone growth stimulator in the region of the cervical spine within the past 30 days
Participation in other investigational device or drug clinical trials within 30 days of surgery
Prisoners
Morbid obesity, defined as body mass index ("BMI") > 40
Type 1 diabetes mellitus requiring daily insulin therapy unless there is documentation of a recent A1c (within 6 months) of less than 7.1 or Type 2 diabetes where the clinical presentation precludes the patient from having surgery
Involved in litigation related to the spine
On workers compensation
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note